ORIC
INSIDER SELLOric Pharmaceuticals, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveORIC demonstrated strong clinical progress with enozimetostat showing best-in-class lung cancer efficacy (84% systemic ORR, 88% 6-month PFS) and rinzimetostat providing differentiated prostate cancer data, supported by robust cash runway (~$345M extending into H2 2028). However, a late-October stock selloff tied to competitive J&J prostate cancer data created near-term volatility, though analyst consensus remains supportive with multiple Buy ratings and price targets ranging $14–$26.
Insider Activity
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G/A | −2.3M | 5.7% | +5.6% vs SPY +2.4% abs | 2026-11-16 | ↗ |
| Point72 | SC 13G/A | — | 0.0% | +62.8% vs SPY +68.3% abs | 2026-05-15 | ↗ |
| Viking Global | SC 13G/A | — | 7.8% | +62.8% vs SPY +68.3% abs | 2026-05-15 | ↗ |